H-Index
17
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

Annals
ISI-Home

Get your full text copy in PDF

Treatment of a patient with severe dysfunction of bioprosthetic heart valves

Maciej Grabowski, Marcin Demkow, Jan Herburt-Heybowicz, Ewa Michalak, Elżbieta Zinka, Irena Rawczyńska-Englert

CaseRepClinPractRev 2003; 4(4):294-298

ID: 449541


Background: Rheumatic heart disease which requires triple valve replacement is seldom seen.To implant
three bioprostheses is rare, because malfunction of the bioprostheses occurs as a result of tissue degeneration in long-term follow up. Where there is stenosis of the valve, percutaneous balloon valvuloplasty can be performed as a palliative measurment. Bioprosthesis dysfunction with severe regurgitation, thrombosis or severe calcification requires valve replacement, but every subsequent operation carries a higher risk.
Case report: We present the case of a 62-year-old woman who underwent triple valve replacement (using
three bioprostheses). After she had developed tricuspid bioprpsthetic stenosis percutaneous
balloon tricuspid valvuloplasty was performed. One year later an aortic graft implatation ( due
to rupture of an aneurysm of the ascending aorta) with triple mechanical valve re-replacement
was performed, but reoperation did not succed.
Conclusions: Percutaneous balloon valvuloplasty (PBV) represents an alternative to surgical treatment for
stenotic bioprosthetic valves. Triple valve reoperation remains a serious problem with a high
mortality rate.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree